Prevalence of Macroprolactinemia in Patients with Hyperprolactinemia Using Roche Elecsys Platform in a Large Tertiary Referral Center in UAE

Abdulla H. Al Nuaimi, R. Almazrouei, Y. Othman, S. Beshyah, Khaled M. Aldahmani
{"title":"Prevalence of Macroprolactinemia in Patients with Hyperprolactinemia Using Roche Elecsys Platform in a Large Tertiary Referral Center in UAE","authors":"Abdulla H. Al Nuaimi, R. Almazrouei, Y. Othman, S. Beshyah, Khaled M. Aldahmani","doi":"10.1159/000519094","DOIUrl":null,"url":null,"abstract":"Objectives: Macroprolactin (macroPRL) excess is an important cause of hyperprolactinemia. Several prolactin assays have high reactivity to macroPRL. However, macroPRL screening is not routinely performed in many labs. This study aimed to evaluate the prevalence of macroprolactinemia (MP) in patients with elevated prolactin using the Roche Elecsys assay in a large tertiary center in UAE. Materials and Methods: Consecutive samples of patients with elevated prolactin presenting to Tawam Hospital from June to August 2018 were evaluated for MP. Polyethylene glycol (PEG) was used to precipitate macroPRL. Monomeric prolactin recovery cutoff ≤50% was used to determine the prevalence of MP. Results: A total of 180 patients with elevated prolactin were included in the study with a mean age of 33.1 ± 11.9 years. The majority were women (87.2%), and about 77.8% were newly diagnosed patients with hyperprolactinemia. The main indications for prolactin testing were menstrual irregularity (n = 121), infertility (n = 11), galactorrhea (n = 11), and sellar masses (n = 12). MP was present in 8.3% of the patients. The median (IQR) of total prolactin level was 740.5 (579–1,085) IU/m before PEG precipitation and was not significantly different between MP and true hyperprolactinemia cases. Three patients with MP had pituitary MRI evaluation, which was normal. Eight patients with MP were treated with cabergoline. Conclusion: One in 12 patients with hyperprolactinemia had MP on the Roche Elecsys assay defined as the cutoff recovery of ≤50% post-PEG precipitation. Physicians should be aware of the prolactin assay used in their labs, and we recommend routine macroPRL assessment in mild hyperprolactinemia samples in labs using the Roche Elecsys platform.","PeriodicalId":34679,"journal":{"name":"Dubai Diabetes and Endocrinology Journal","volume":"123 1","pages":"126 - 130"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dubai Diabetes and Endocrinology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000519094","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Objectives: Macroprolactin (macroPRL) excess is an important cause of hyperprolactinemia. Several prolactin assays have high reactivity to macroPRL. However, macroPRL screening is not routinely performed in many labs. This study aimed to evaluate the prevalence of macroprolactinemia (MP) in patients with elevated prolactin using the Roche Elecsys assay in a large tertiary center in UAE. Materials and Methods: Consecutive samples of patients with elevated prolactin presenting to Tawam Hospital from June to August 2018 were evaluated for MP. Polyethylene glycol (PEG) was used to precipitate macroPRL. Monomeric prolactin recovery cutoff ≤50% was used to determine the prevalence of MP. Results: A total of 180 patients with elevated prolactin were included in the study with a mean age of 33.1 ± 11.9 years. The majority were women (87.2%), and about 77.8% were newly diagnosed patients with hyperprolactinemia. The main indications for prolactin testing were menstrual irregularity (n = 121), infertility (n = 11), galactorrhea (n = 11), and sellar masses (n = 12). MP was present in 8.3% of the patients. The median (IQR) of total prolactin level was 740.5 (579–1,085) IU/m before PEG precipitation and was not significantly different between MP and true hyperprolactinemia cases. Three patients with MP had pituitary MRI evaluation, which was normal. Eight patients with MP were treated with cabergoline. Conclusion: One in 12 patients with hyperprolactinemia had MP on the Roche Elecsys assay defined as the cutoff recovery of ≤50% post-PEG precipitation. Physicians should be aware of the prolactin assay used in their labs, and we recommend routine macroPRL assessment in mild hyperprolactinemia samples in labs using the Roche Elecsys platform.
在阿联酋的一个大型三级转诊中心使用罗氏Elecsys平台研究高催乳素血症患者中巨催乳素血症的患病率
目的:巨催乳素(macroproactin, macroPRL)过量是导致高催乳素血症的重要原因。几种催乳素测定法对macroPRL有很高的反应性。然而,在许多实验室中,macroPRL筛查并不是常规的。本研究旨在评估在阿联酋的一个大型三级中心使用罗氏Elecsys检测的泌乳素升高患者中巨催乳素血症(MP)的患病率。材料与方法:对2018年6月至8月在Tawam医院连续就诊的催乳素升高患者进行MP检测。聚乙二醇(PEG)用于沉淀macroPRL。采用单体催乳素恢复截止值≤50%判定MP的患病率。结果:共纳入泌乳素升高患者180例,平均年龄33.1±11.9岁。大多数是女性(87.2%),约77.8%是新诊断的高泌乳素血症患者。催乳素检测的主要适应症为月经不调(n = 121)、不孕(n = 11)、溢乳(n = 11)、鞍块(n = 12)。8.3%的患者存在MP。聚乙二醇沉淀前总催乳素水平的中位数(IQR)为740.5 (579 - 1085)IU/m, MP与真正的高催乳素血症之间无显著差异。3例MP患者垂体MRI检查正常。8例MP患者接受卡麦角林治疗。结论:每12例高泌乳素血症患者中就有1例在罗氏Elecsys检测中出现MP,定义为peg沉淀后的截止回收率≤50%。医生应该了解实验室中使用的催乳素测定,我们建议在实验室中使用罗氏Elecsys平台对轻度高催乳素血症样本进行常规大prl评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
14
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信